Biotech Cycle: XBI Up 38% YTD, 3% From Record High

Here is the number that tells you where biotech actually sits right now: the XBI closed at $168.23, up 38.4% year to date from $121.52, and within 3% of its all-time high near $174 from February 2021. The sector has nearly doubled off its August 2025 low of $89.85. If you are waiting for a sign that the funding winter ended, stop waiting. It ended. The question that actually matters now is not whether the cycle turned. It is how late the cycle is, and whether the easy money has already been made.

The honest answer is uncomfortable for both camps. The perma-bears who stayed in cash for all of 2026 missed an 87% rally off the bottom. The perma-bulls who are chasing the narrative-tier IPOs that popped triple digits are buying the frothiest part of the cycle. The correct read is in the middle: this is a late-recovery market, not a top, and the window is open but not yet crowded. Here is the full state of play.

The Cycle Has a Shape, and It Repeats

Biotech moves in a four-act cycle, and every act has a leading indicator that tells you the transition is coming before the prices do.

Act one is the funding winter. Capital dries up, IPOs stop, and companies burn cash at fire-sale valuations. The leading indicator that it is ending is not a single drug readout. It is the Federal Reserve stopping the rate hikes. In 2022 the Fed went from near zero to 5.25-5.50% in the fastest hiking cycle in 40 years, the 10-year Treasury yield shot past 4%, and XBI fell 63.89% peak to trough. By late 2022, biotech funding had collapsed to $10.9 billion a quarter, and only 8 companies went public in all of 2025. That was the winter.

Act two is the IPO reopening. The window does not open all at once. It opens de-risked first. Act three is the M&A wave, where Big Pharma, staring down a patent cliff it cannot fill with internal R&D, starts writing checks. Act four is the peak, where narrative names with no data pop triple digits and retail piles in. The leading indicator for the peak is not a crash. It is euphoria priced into companies that have no business being up 100%.

The point of knowing the shape is that you stop asking the wrong question. “Is biotech back?” is not a question. The question is which act the cycle is in.

The Four Signals, Read at Once

As of late August 2026, all four signals are pointing the same direction, but they are not all pointing at the same level of confidence.

First, the IPO window is genuinely open. Twenty biotech IPOs have priced in 2026 for roughly $6.4 billion in proceeds, already the busiest year since the 2021 pandemic peak, and analysts expect 30 to 35 total. Q1 alone raised $1.7 billion, the most of any quarter since 2021. The August wave of BlossomHill, Latigo, Braveheart, and Attovia raised over $1.1 billion in a single week, on top of Apnimed, Scribe, and Vogenx. This is the clearest signal that the winter is over, and the full breakdown of the reopening wave is here.

Second, funding is compounding. Biotech raised $34.3 billion in Q2 2026, a fourth straight quarter of growth and more than triple the $10.9 billion trough of late 2022. The capital is not being distributed evenly. Venture investors are concentrating into de-risked, later-stage assets with clinical proof, which is why the de-risked tier of IPOs is outperforming the narrative tier on quality while underperforming it on price. That split is the difference between a healthy recovery and a blow-off top.

Third, the M&A engine is firing. The patent cliff is the structural reason: an estimated $236 billion in branded pharma revenue loses patent protection between 2026 and 2030, led by Keytruda, Eliquis, Opdivo, and Ibrance. Internal R&D cannot fill a hole that size. So Big Pharma is buying instead. 2026 is on pace for $212 billion in deals, with Vertex paying $10 billion for Crinetics, GSK paying $10.6 billion for Nuvalent, Novartis paying $11.4 billion for Avidity, and J&J paying $14.7 billion for Intra-Cellular. The full screen for what Big Pharma buys and why is here.

Fourth, and this is the wildcard, rates are still the thing nobody wants to talk about. The 10-year Treasury yield is 4.66%, and the Fed is holding at 3.50-3.75% with only one dot projecting a cut this year. Biotech has rallied 38% this year with the risk-free rate still above 4%. That is unusual. The rally is being carried by falling rate expectations and the fading of the 2022 fear, not by a realized easing cycle. If the Fed disappoints or the yield pushes back toward 5%, the most rate-sensitive names in the sector, the pre-revenue platforms with 2028 catalysts, get repriced first. The interest-rates and biotech valuation math that explains why is here.

What This Means for Where You Put Money

The cycle position dictates the strategy. The market is in act three, the M&A wave, with act two, the IPO reopening, still running. The market is not yet in act four. The evidence that the cycle has not topped is what the market is rewarding versus what it is not.

Right now the market is paying up for the narrative tier. Scribe is up 108% from its IPO with zero efficacy data. Vogenx is up 142% on a rival’s Phase 3 win. Meanwhile Apnimed, which has two Phase 3 wins and a PDUFA date, is up 71%, and Latigo is up 25% with Phase 2 data on a validated target. When the market overpays stories and underpays data, you are in a healthy, if uneven, recovery, not a blow-off top. A blow-off top pays up for everything, including the names with nothing.

So the move is not to go all-in or all-out. It is to rotate. Overweight the de-risked tier: companies with Phase 3 data, a PDUFA date, or an FDA approval, priced under $5 billion, sitting in a therapeutic area where a Big Pharma acquirer has a patent cliff. Those are the names that win in act three, because they are both investable standalone and the exact assets Big Pharma is paying 50-100% premiums to acquire. Underweight the narrative tier: the Phase 1 story stocks that popped triple digits on the open window. They are trades, not holdings, and they give it back when the IPO lockups expire in early 2027.

For the sector exposure itself, the construction choice matters more than the sector call. XBI is equal-weight and tilts small-cap, which is why it is up 38% while the cap-weighted IBB, dominated by Amgen, Gilead, Vertex, and Regeneron, has been steadier. If you want the cycle beta, you want the equal-weight fund. If you want the mega-cap floor, you want the cap-weight fund. The three ETFs are not interchangeable, and the guide is here.

The Honest Forward View Into 2027

Here is the contrarian part, and it is the part most cycle commentary gets wrong. The setup for 2027 is not obviously bullish just because 2026 has been. The IPO window is open, the M&A wave is building, and the 2027 catalyst calendar is already dense with PDUFA dates and Phase 3 readouts. That is the bull case. But cycles do not announce their top, and this cycle is being carried by rate expectations at a moment when the 10-year is still 4.66% and the Fed has not actually cut.

The question for late 2026 is not “which stock doubles next.” It is “what breaks first if the 10-year yield climbs back toward 5%.” The answer is the same names that led the rally: the pre-revenue platforms and the narrative IPOs. The de-risked tier with hard catalysts inside 12 months is comparatively insulated, because a PDUFA date in three months is worth more than a rate move.

The positioning call is specific: be greedy, but be greedy in the right pocket. Scale into the de-risked, late-stage, sub-$5 billion names with catalysts in the next 12 months, the exact profile Big Pharma is buying, and trim any narrative-tier name you are holding above its IPO price. Keep 20-30% dry powder, because if this rally does reach the euphoria of act four in 2027, the dry powder is what lets you buy quality names at half price when the cycle inevitably corrects. The winter is over, but that is exactly when the discipline matters most.